Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Publication | Closed Access

DOI

110

Citations

References

2020

Year

Markus Moehler, Annett Maderer, Peter Thuss‐Patience, Baruch Brenner, Jens Meiler, Thomas J. Ettrich, Ralf‐Dieter Hofheinz, S. Al-Batran, Arndt Vogel, Lothar Mueller,

Annals of Oncology